ERBB2 and breast carcinoma: The safety and efficacy of androgen-targeted therapies with standard of care systemic therapies, such as trastuzumab for patients with advanced HER2+ breast cancer [13], and exemestane for those with hormone receptor (HR) positive disease, have also been evaluated [14].